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In Brief
Peripheral neuropathy is a clinically
variable and genetically heterogeneous
disease. In a cohort of patients, Gonzaga-
Jauregui et al. have identified causative
variants in 45% of the families studied,
proposed candidate disease genes for an
additional three families, and recognized
a significant mutation burden in patients
versus controls that likely contributes to
phenotypic variability.
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Charcot-Marie-Tooth (CMT) disease is a clinically
and genetically heterogeneous distal symmetric
polyneuropathy. Whole-exome sequencing (WES)
of 40 individuals from 37 unrelated families with
CMT-like peripheral neuropathy refractory to molec-
ular diagnosis identified apparent causal mutations
in 45% (17/37) of families. Three candidate disease
genes are proposed, supported by a combination of
genetic and in vivo studies. Aggregate analysis of
mutation data revealed a significantly increased
number of rare variants across 58 neuropathy-asso-
ciated genes in subjects versus controls, confirmed
in a second ethnically discrete neuropathy cohort,
suggesting that mutation burden potentially con-
tributes to phenotypic variability. Neuropathy genesCellshown to have highly penetrant Mendelizing variants
(HPMVs) and implicated by burden in families were
shown to interact genetically in a zebrafish assay
exacerbating the phenotype established by the sup-
pression of single genes. Our findings suggest that
the combinatorial effect of rare variants contributes
to disease burden and variable expressivity.INTRODUCTION
Charcot-Marie-Tooth (CMT) disease, first described clinically
in 1886 (Charcot and Marie, 1886; Tooth, 1886), is a common
hereditary peripheral neuropathy with an estimated preva-
lence of one in 1,200 (Braathen, 2012) to one in 2,500 (Skre,
1974) individuals. The disease is characterized by distal sym-
metric polyneuropathy (DSP) with progressive muscle weak-
ness and atrophy, as well as sensory loss. Two major clinicalReports 12, 1169–1183, August 18, 2015 ª2015 The Authors 1169
types are distinguished by electrophysiologic and neuropatho-
logic studies and the type of cells (glia or neurons) primarily
affected. CMT1 affects the glia-forming Schwann cells and pre-
sents with nerve conduction velocities (NCV) of <38 m/s; CMT2
affects the axons of neurons and usually presents with NCVs
of >38 m/s or slightly reduced motor NCVs but with diminished
amplitudes. Other forms of CMT with additional clinical features
have been described, including an intermediate form with over-
lapping demyelinating and axonal CMT features (Nicholson and
Myers, 2006) and one in which CMT occurs in conjunction with
glomerulonephritis (Boyer et al., 2011).
The observed inheritance patterns include autosomal domi-
nant, autosomal recessive, and X-linked (dominant and reces-
sive) forms (Allan, 1939; Rossor et al., 2012). Nevertheless, most
patients present with apparent sporadic disease, attributable
partially to the extreme clinical variability and age-dependent
penetrance of the phenotype. New mutation, however, is often
the cause of sporadic CMT, with the de novo CMT1A duplication
of 17p11.2 being responsible for 76%–90% of sporadic cases
(Raeymaekers et al., 1991; Lupski et al., 1991; Hoogendijk et al.,
1992; Nelis et al., 1996). Locus-specific screening for mutations
in knownCMTgenesconcludesamoleculardiagnosis for approx-
imately 70%–80% of patients (Szigeti and Lupski, 2009; DiVin-
cenzoet al., 2014).More than40genesareknown tobecausative,
but it has been estimated that 30–50 ‘‘CMT genes’’ remain to be
discovered (Braathen, 2012; Timmerman et al., 2014).
CMT1A (MIM #118220) is caused by a recurrent 1.4-Mb dupli-
cation that encompasses the dosage-sensitive myelin gene
PMP22 (Lupski et al., 1991; Hoogendijk et al., 1992; Patel
et al., 1992; Lupski et al., 1992), an essential component of
compact peripheral nervous system (PNS) myelin (Li et al.,
2013). The reciprocal deletion of the identical 17p11.2 region
causes hereditary neuropathy with liability to pressure palsies
(HNPP) (MIM #162500) (Chance et al., 1993, 1994). A recent
study of 17,000 patients with neuropathy established a molecu-
lar diagnosis in 18.5% of these; 80% of molecular diagnoses
were either duplication or deletion of PMP22 (DiVincenzo et al.,
2014). Point mutations and indels in PMP22 have also been
found in patients with CMT1A or HNPP without duplication or
deletion (Roa et al., 1993a; Nicholson et al., 1994), and in the
more severe early-onset phenotype of hypertrophic neuropathy
of Dejerine-Sottas (MIM #145900) (Dejerine and Sottas, 1893;
Roa et al., 1993a, 1993b; Li et al., 2013). Additionally, non-recur-
rent and complex rearrangements can account for the missing
heritability in CMT1A and HNPP, including upstream copy-num-
ber variants (CNVs) that do not include PMP22 coding sequence
(Zhang et al., 2010; Weterman et al., 2010).
The second most common form of CMT is CMTX1 (MIM
#302800) caused primarily by point mutations that occur in
almost every amino acid of GJB1/connexin32 (Kleopa and
Scherer, 2006; Scherer and Kleopa, 2012); gene deletions
have also been described (Gonzaga-Jauregui et al., 2010).
GJB1 encodes a gap junction protein involved in the formation
of connexon hemichannels that facilitate the communication
and exchange of ions and other small molecules between
Schwann cells and axons (Scherer and Kleopa, 2012).
The third most common cause of CMT, and the most com-
mon form of CMT2, are heterozygous mutations in MFN21170 Cell Reports 12, 1169–1183, August 18, 2015 ª2015 The Autho(CMT2A; MIM #609260) (Ben Othmane et al., 1993; Zu¨chner
et al., 2004; Verhoeven et al., 2006), essential for mitochon-
drial fusion and function (Kijima et al., 2005) and maintenance
of mitochondrial morphology. Mutations in MFN2 lead to mito-
chondrial dysfunction due to mtDNA depletion (Vielhaber et al.,
2013). Mutations in GDAP1 cause a recessive form of CMT,
which can be either demyelinating (CMT4A; MIM #214400)
(Cuesta et al., 2002), axonal (CMT2K; MIM #607831) (Nelis
et al., 2002) or intermediate (CMTRIA; MIM #608340) (Send-
erek et al., 2003) and have been reported to affect mitochon-
drial fission in Schwann cells and neurons (Niemann et al.,
2005).
Known CMT genes encode proteins that span a wide range
of functions, from GTPases (RAB7, DNM2), lipid phosphatases
(FIG4, MTMR2), to structural myelin proteins (MPZ, PMP22)
and gap junction channel components (GJB1). Cellular
functions include myelin assembly (PMP22, MPZ, PRX, Cx32),
membrane and endocytic trafficking (MTMR2, SBF2, FIG4,
SH3TC2) and mitochondrial dynamics (MFN2, GDAP1) (Nie-
mann et al., 2005; Azzedine et al., 2012). Another predominant
contributing gene group is that of aminoacyl-tRNA synthetases,
an essential class of enzymes that ligate amino acids onto
cognate tRNA molecules (reviewed in Wallen and Antonellis,
2013).
Other complex forms of CMT2 (e.g., spinocerebellar ataxia
with axonal neuropathy, SCAN1) have been associated with
mutations in TDP1, important for DNA single-strand break repair
(SSBR) (McKinnon and Caldecott, 2007; Caldecott, 2008).
Mutations in SETX, a helicase involved in transcriptional termina-
tion and RNA maturation, cause recessive ataxia ocular motor
apraxia type 2 (AOA2; MIM #606002) (Moreira et al., 2004)
possibly due to transcriptional/translational defects (Anheim
et al., 2012), also disturbing DNA SSBR (Caldecott, 2008).
SETXmutations have been associated with familial amyotrophic
lateral sclerosis (ALS), susceptibility that recently was also asso-
ciated with heterozygous FIG4 mutation carrier states (Chow
et al., 2009).
Substantial genetic and clinical heterogeneity of CMT neurop-
athy makes it challenging for molecular diagnosis by single gene
and gene panel testing; the diagnostic utility of genome-wide
sequencing approaches has been demonstrated (Lupski et al.,
2010; Montenegro et al., 2011; Choi et al., 2012; Lupski et al.,
2013). We performed whole-exome sequencing (WES) in a
cohort of 40 patients with peripheral neuropathy from 37 unre-
lated families in whom extensive genetic evaluation had failed
to identify a causative mutation or establish a molecular diag-
nosis (Tables 1 and S1). Analysis of WES data was performed
in two stages: a first-pass analysis that focused on known or
novel variants in known CMT and related neuropathy genes,
and a second stage analysis to search for rare variants in likely
novel candidate genes (Figure S1). Our rare variant analyses
revealed potential neuropathy candidate ‘‘disease genes.’’ Sur-
prisingly, we uncovered evidence for a mutational burden in
affected individuals versus a large sample of unrelated control in-
dividuals. We show experimentally that genetic interactions
implicated by burden contribute to phenotypic variability and
potentially to susceptibility to common neuropathies beyond
the well-characterized Mendelian forms.rs
Table 1. Personal Exome Findings in Neuropathy Genes Reveal Highly Penetrant Mendelizing Variants (HPMVs) Driving Disease,
Additional Genes Harboring Rare Variants, and Diagnosis Based On Molecular Findings
BAB # Clinical Dx
Main Mutation(s) Identified
(HPMV)
Additional Genes with Rare
Variants Molecular Dx [MIM #]
Known genes, known variants
668 CMT2 MFN2 (p.W740S)b MED25, IKBKAP, TRPV4 CMT2A2 [609260]
710 CMT2 MED25 (p.A335V)b; (p.P656T)c ATP7A, SH3TC2 CMT2B2 [605589]
1405 CMT1 MFN2 (p.V244M)b [de novo] WNK1 CMT2A2 [609260]
1564 CMT2 MFN2 (p.V244M)b [de novo] HSPB1, NARS2, TARS CMT2A2 [609260]
3656 (T) CMT2 AARS (p.R329H)b SFB2 CMT2N [613287]
3662 (T) CMT2 MFN2 (p.C281S)b SBF2, INF2, KIF1B CMT2A2 [609260]
3663 (T) CMT1 MPZ (p.I135L)b - CMT1B [118200]
Known genes, novel variants
1080 CMT MFN2 (p.R649P)c GDAP1, DNMT1 CMT2A2 [609260]
1280 CMT2 ARHGEF10 (p.G132S)c CARS2 AD slowed nerve conduction
velocity [608236]
1500 Dejerine Sottas SH3TC2 (p.K274X)c [hmz] DNM2 CMT4C [601596]
1955 CMT2 AIFM1 (p.R463I)c AARS, KIF1B, WNK1 Cowchock syndrome [310490]
3646 CMT intermediate YARS (p.E196Q)c DNMT1, MARS CMTDIC [608323]
3647 CMT intermediate YARS (p.E196Q)c DNMT1, MARS CMTDIC [608323]
3657 (T) CMT1 GJB1 (IVS1-2A>G)c LRSAM1, PRX, VARS2 CMTX1 [302800]
3660 (T) CMT2 MFN2 (p.V160G)c SETX CMT2A2 [609260]
3672 (T) CMT2 MFN2 (p.G176S)c [hmz] LRSAM1 CMT2A2 [609260]
4119 (T) CMT2 TRIM2 (p.D667A) [hmz]a - CMT2R [615490]
Phenotypic re-assessment
996 congenital hypomielinating
neuropathy/ataxia
ITPR1 (p.G2547A)c MTMR2, WNK1 SCA29 [117360]
1038 CMT/Dejerine-Sotas SURF1 (p.Q196X);
(p.L105Rfs*11)c
PRX, SBF2, NEFL, NGF,
MYH14
Leigh syndrome/ demyelinating
peripheral neuropathy [256000]
1163 hypotonia, hypomyelinating
neuropathy
ADCY6 (p.Y992C)c [hmz] - arthrogryposis multiplex
congenita with axoglial defects
1522 CMT MYH14 (p.R941L)b - PNMHH [614369]
1566 congenital hypotonia IGHMBP2 (p.C496X)b;
(p.M449Sfs*24)c
NEFL, SETX, SEPT9,
YARS2
DSMA1/ SMARD1 [604320]
1581 congenital hypomyelinating
neuropathy
IGHMBP2 (p.E514K)b,
(p.A256G)c; (p.A398E)c
SBF2, FIG4, NTRK2,
FARSB
DSMA1/ SMARD1 [604320]
1680 neuropathy, ataxia, cataracts ABHD12 (14kb del)b [hmz] GDAP1, WNK1 PHARC [612674]
2447 progressive neuro-
degenerative disorder
SETX (p.Q2108X)c [hmz] - AOA2/ SCAR1 [606002]
3664 (T) CMT2 AIMP1 (p.Q112X)c [hmz] - hypomyelinating leukodystrophy (HLD3)
3669 (T) CMT2 DNAJB2 (c.619-1G>A) [hmz] SETX, IGHMBP2 DSMA5 [604139]
3729 (T) CMT2 TFG (p.P285L)b - HMSNO [604484]
3730 (T) CMT2 DNAJB2 (p.F103fs)c [hmz] - DSMA5 [604139]
Potential novel candidate genes
124 hereditary myoclonus and
progressive distal muscular
atrophy
DNAJB5 (p.P15S) GARS, TRPV4, RARS2 NA
1468 CMT1 PMP2 (p.I43N) PRX, VARS NA
1631 CMT SPTLC3 (p.W150R) MED25, SH3TC2, PRX NA
Abbreviations are as follows: T, patient from Turkish cohort; Dx, diagnosis; HPMV, highly penetrant Mendelizing variant; NA, not applicable. Classi-
fication of ‘‘known genes, known variants’’ and ‘‘known genes, novel variants’’ refers to the HPMV.
aPreviously published (Pehlivan et al., 2015).
bKnown mutation.
cNovel mutation in known gene.
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Figure 1. Pedigrees of CMT/Neuropathy Patients and Segregation of Causative Mutations
(A) Pedigree showing de novo occurrence of the known p.V244M MFN2 mutation in proband.
(B) Dominant pedigree of a dominant intermediate form of CMT and segregation of the identified novel variant p.E196Q in YARS. Mutation was inherited to the
affected proband and affected sister from the affected mother.
(C) Pedigree of a dominantly inherited myopathy-neuropathy phenotype in a family with multiple affected individuals where a novel variant in DNAJB5 (p.P15S)
was identified.
(D) Pedigree of a dominant form of CMT and segregation of the mutation in candidate gene PMP2 (p.I43N). The affected proband inherited the mutation from his
affected father, while both the unaffected mother and sister do not carry the mutation.RESULTS
Known Alleles in Known Neuropathy Genes
We identified known disease-causing alleles, both single nucle-
otide variants (SNV) and exonic deletion CNV, in six of the 37
index patients (see Supplemental Information for detailed clinical
information). Two represented phenotypic expansions of CMT2
caused by mutations inMFN2 (Figure 1A), where the clinical pre-
sentation made screening forMFN2 unlikely. One family showed
two separate segregating causes of CMT (Verny et al., 2004),1172 Cell Reports 12, 1169–1183, August 18, 2015 ª2015 The Authoone X-linked and the other caused by compound heterozygous
mutations in MED25. A novel, likely disease-causing allele was
found in trans with the only known disease-causing allele in
this gene (Leal et al., 2001, 2009). In a proband with autosomal
dominant neurosensory deafness and axonal neuropathy, we
found a recently reported mutation in MYH14 (Choi et al.,
2011). Finally, in a consanguineous family, we detected a 14-
kb homozygous deletion CNV encompassing exon 1 of
ABHD12 segregating with the complex neuropathy phenotype
observed in the proband and affected siblings (Fiskerstrandrs
et al., 2010) (Figure S2). An additional homozygousGDAP1 novel
variant was also identified in some affected individuals of this
family posing the possibility of an additive contribution from
intragenic deletion CNV plus SNV variation.
Novel Alleles in Known Neuropathy Genes
Rare non-synonymous, frameshifting, or splicing variants were
identified in known CMT/neuropathy disease genes, illustrating
the complexity that can underscore ‘‘simple’’ Mendelian condi-
tions (see Supplemental Information for detailed clinical informa-
tion). We identified a patient with mutations in both MFN2 and
GDAP1, both of which are involved in mitochondrial dynamics.
Concurrent mutations in these genes have been reported,
suggesting the possibility of epistasis or modifying effects (Cas-
sereau et al., 2011; Vital et al., 2012). In a family with three gen-
erations affected by autosomal dominant intermediate CMT, we
sequenced two individuals and identified a novel variant in YARS
affecting a residue previously reported to be mutated in disease
(Jordanova et al., 2006) (Figure 1B). Functional analyses re-
vealed that the identified YARS allele is a functional hypomorph,
unable to complement fully deletion of the endogenous yeast
gene, TYS1, in growth complementation assays (Figure S3), sup-
porting a pathogenic role for this mutation in CMT. Amale patient
with Sotos syndrome (MIM #117550) due to NSD1 deletion plus
clinical neuropathy was found to carry several predicted delete-
rious variants in different CMT genes in addition to a novel poten-
tially pathogenic variant in the X-linked AIFM1 gene (Rinaldi
et al., 2012). Compound heterozygous truncating mutations in
SURF1 were identified in a proband with demyelinating CMT.
Loss-of-function mutations in SURF1 were recently described
in patients with autosomal recessive severe demyelinating
neuropathy of childhood onset (Echaniz-Laguna et al., 2013),
consistent with this patient’s clinical and molecular findings.
Genetic and Functional Evidence for Potential
Candidate CMT Genes
We identified variant alleles implicating three potential new
candidate neuropathy genes, PMP2, SPTLC3, and DNAJB5, in
three different families. In a family with a clinical diagnosis
of autosomal dominant demyelinating CMT1 neuropathy, we
found a candidate missense variant in myelin protein P2,
PMP2 (c.T128A; p.I43N) as the most likely disease-causing
variant.We confirmed this variant in the proband and his affected
father, and its absence in both unaffectedmother and sister (Fig-
ure 1D). PMP2 is a major stabilizing component of the myelin
sheath that insulates the axons in the PNS (Majava et al., 2010)
but to date has not been associated with any genetic peripheral
neuropathy. PMP2 is predominantly expressed in myelinating
Schwann cells, with specific expression in sciatic nerve endo-
neurium and dorsal root ganglia (Zenker et al., 2014). Homozy-
gous knockout (Pmp2/) mice have significantly reduced
temporal motor nerve conduction velocities, although no major
structural changes in the myelin sheath and peripheral nerves
were observed (Zenker et al., 2014).
In vivo modeling experiments interrogated the potential
impact of PMP2 loss of function and of this specific novel variant.
Two orthologs exist in zebrafish; suppression of either using
morpholino (MO) knockdown led to a motor neuron phenotype,Cellincluding failure of the motor neuron axons to extend from the
notochord, as well as pathfinding errors where the axons failed
to innervate the myotomes appropriately (Figures 2A and 2B).
These phenotypes could be rescued by co-injection of the MO
with wild-type human PMP2; however, contrary to wild-type,
humanmRNA carrying the variant identified in our proband failed
to restore the MO-induced phenotype (Figures 2A–2E). Upon
overexpression, wild-type human mRNA induced a phenotype
similar to the one observed with MO alone in >50% of injected
embryos, suggestive of a dosage-sensitive transcript, similar
to PMP22. Overexpression of human mutant (p.I43N) PMP2
mRNA exacerbated the phenotype significantly (20% increase;
p = 0.0003 Figures 2E and 2F); consistent with a dominant-nega-
tive mechanism of pathogenesis for this allele.
Of note, antibodies against PMP2 fragments were identified
initially in experimental allergic neuritis, an autoimmune periph-
eral neuropathy in animals like rats and rabbits, and a model
for Guillain-Barre syndrome (GBS) (Ishaque et al., 1981, 1982).
One of themain characteristics of GBS is the autoimmune attack
to the peripheral nerves’ myelin sheath causing demyelination.
Antibodies against myelin protein zero (MPZ, P0) and most
significantly to myelin protein 2 (PMP2, P2) have been detected
in patients with GBS and chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) characterized by primary demy-
elination and lymphocytic infiltration of the peripheral nerve
(Inglis et al., 2007). Thus, discovery of this mutation in a CMT
patient suggests a potential mechanistic link between auto-im-
mune neuropathy and inherited neuropathy.
We identified a novel variant in SPTLC3 (c.T448C; p.W150R)
changing a highly conserved residue and predicted to be
damaging by bioinformatic algorithms in a patient; no parental
samples were available. The proband presented with neu-
ropathy with a marked sensory but no apparent autonomic
involvement. SPTLC3 is the third subunit of the serine palmitoyl-
transferase enzyme (SPT) involved in the de novo biosynthesis of
sphingolipids (Hornemann et al., 2009). Heterozygous mutations
in subunit 1 of SPT, SPTLC1, were first identified as the cause
of hereditary sensory and autonomic neuropathy type 1A
(HSAN1A; MIM #162400) (Dawkins et al., 2001). Both genes en-
coding the additional subunits of SPT, SPTLC2 and SPTLC3,
were screened for mutations in a cohort of typical HSAN
patients. Heterozygous missense mutations were identified in
SPTLC2 in a fraction of patients but no mutations were found
in SPTLC3 (Rotthier et al., 2010). Consistent with a neuropathy
‘‘disease gene,’’ suppression of the sptlc3 ortholog in zebrafish
embryos showed motor neuron axon defects that phenocopied
suppression of other known CMT genes (Figures 2H and 2I).
The specific phenotype could be rescued by co-injection with
SPTLC3 wild-type human mRNA (Figures 2H–2L). Injection of
human mRNA carrying the variant identified in the proband
was unable to rescue the phenotype, supporting the contention
that the missense variant represents a hypomorphic or possible
loss-of-function allele (Figures 2H–2L).
In a large family with an inheritance pattern consistent with an
autosomal dominant myopathy/neuropathy, we identified ten
shared variants in three affected individuals, of which nine did
not segregate with the disease. A novel variant in DNAJB5
(c.C43T; p.P15S) was the only rare variant that co-segregatedReports 12, 1169–1183, August 18, 2015 ª2015 The Authors 1173
Figure 2. Suppression of pmp2 and sptlc3 in Zebrafish Causes Defects in Motor Axon Pathfinding and Outgrowth
(A–F) Lateral views of a control embryo, an embryo injected with pmp2 morpholino (MO) and embryos injected with pmp2 MO+PMP2_WT and pmp2
MO+PMP2_I43N, PMP2_WT and PMP2_I43N cocktails, respectively, at 2 dpf (days post fertilization). Controls showed even spacing and normal branching of the
motor neuron axons (A). In the pmp2MO-injected embryos, the spacing of neuronal axons is perturbed by exiting the periphery but failing to extend (asterisks) or
presenting pathfinding errors (arrows; B). Co-injection of pmp2 MO with human PMP2_WT resulted in restoration of the normal neuronal phenotype (C), but
PMP2_I43N did not (D). Overexpression of human PMP2_WT causes mild pathfinding errors (E), suggesting dose sensitivity for PMP2. However, the human
PMP2 mutant p.I43N was significantly more severe than PMP2_WT when overexpressed (F) and had similar effects to suppression of pmp2 by MO knockdown.
(G) Percentage of normal versus abnormal embryos under the conditions being evaluated above.
(H–K) Wild-type embryos (H) and sptlc3 morphants (I) in which secondary axons fail to migrate appropriately (white arrows). The phenotype induced by sup-
pression of sptlc3 could be rescued by co-injection with SPTLC3_WT (J) but not SPTLC3_R150W (K).
(L) Quantification of normal embryos versus embryos with motor neuron axon defects. For statistical analyses, c2 tests were performed.with the phenotype (Figure 1C). This rare variant was observed in
four other independent individuals in our exome database of
3,000 individuals; however, no phenotypic information is avail-
able for these individuals. The variant is also present in the het-
erozygous state in a single individual in the Exome Aggregation
Consortium (ExAC) compiled data set (MAF = 0.00004858).
This DNAJB5 variant affects a highly conserved amino acid
in the DnaJ domain of the protein. A homozygous mutation in
DNAJB2 was identified in a large family segregating recessive
distal hereditary motor neuropathy of early adulthood onset
(Blumen et al., 2012). Mutations inDNAJB6 have also been impli-
cated in autosomal dominant myopathy (Harms et al., 2012; Sar-
paranta et al., 2012) and have a dominant-negative toxic effect
increasing the stability of the cytoplasmic form of the protein
and interfering with its chaperone function (Sarparanta et al.,
2012). These three genes encode members of the HSP40/
DNAJ family ofmolecular co-chaperones, which protect proteins
from irreversible aggregation during protein synthesis or molec-1174 Cell Reports 12, 1169–1183, August 18, 2015 ª2015 The Authoular stress. Functional testing of this gene by MO knockdown in
zebrafish showed abnormal peripheral nerve axonal architec-
ture supporting a role of this gene in peripheral nerve patho-
physiology but had no apparent effect on muscle architecture
(Figure S4). We propose DNAJB5 as a potential candidate for
myopathy/neuropathy based on its relationship with previously
reported genes involved in similar phenotypes; HSPB8 (HSP27)
andHSPB1 (HSP22) are known genes associatedwith peripheral
neuropathy (Evgrafov et al., 2004; Irobi et al., 2004).
Rare Variant Contributions to Phenotypic
Manifestations: Evidence for a Mutation Burden
WES of neuropathy patients often identified more than one rare
variant in a neuropathy gene within a given personal genome
(Tables 1 and S2). As described above, we identified the
predominant highly penetrant Mendelizing variants (HPMV) in
multiple patients, as evidenced by co-segregation with disease
or de novo appearance in sporadic neuropathy. However, wers
Figure 3. Neuron Schematic of the Locali-
zation or Site of Action of the Main CMT/
Neuropathy Gene Products
Legend on left shows patient identifier numbers
and causative and possibly contributingmutations
identified by WES. Full shapes correspond to rare
presumed causative mutations deemed Highly
Penetrant Mendelizing Variants (HPMVs), while
empty shapes correspond to rare variants that
may be contributing to the mutation burden in
neuropathy patients. Each personal genome is
distinguished by a unique color/shape. In boldface
are some of the canonical CMT genes. Abbrevia-
tions: CB, neuron cell body; A, axon; SC, Schwann
cell; NR, node of Ranvier; mt, mitochondria; M,
myelin.also identified potential contributing or modifying rare variants in
other neuropathy-associated genes (Figure 3). These latter rare
variants are not likely the mutations predominantly responsible
for trait manifestation because they are inherited from an unaf-
fected parent or do not conform to Mendelian expectations
(i.e., exceptions to co-segregation with neuropathy in the family).
For example, we observed a higher than expected heterozygous
carrier frequency of the reported MED25 (p.A335V) mutation
in our cohort (10% of patients; MAF = 5.0%) compared to that
observed in the NHLBI ESP study sample (65/6,498 individuals;
MAF = 0.5% [p value = 0.001]), a group of 266 controls (two
of 266 individuals; MAF = 0.375% [p value = 0.003]), and the
ARIC European-American (ARIC-EA) study participants (80/
5,748 individuals; MAF = 0.7% [p value = 0.003]). Although in
three of four cases in our patient cohort, there is no ‘‘second
hit’’ inMED25 to cause the CMT2B2 phenotype, we cannot dis-
count the possibility of a second pathogenic non-coding variant
not captured by WES or the potential contribution of this muta-
tion in a mutational aggregation model to the overall phenotype
of these patients.
Of note, we identified an average of 2.3 nonsynonymous rare
variants per individual in 58 known neuropathy-associated genes
in the entire patient cohort (40 samples) versus 1.3 nonsynony-
mous rare variants in 5748 ARIC-EA control individuals
(p < 0.0001; Figure 4A). Cases with a definitive molecular diag-
nosis had an average of 2.9 variants per individual (including the
HPMV), while the undetermined cases had an average of 1.8 var-
iants per individual. After implementing a stringent filter wherewe
subtracted the HPMV of each molecularly defined case, we stillCell Reports 12, 1169–1183,found an average of 1.8 variants in the
CMT cohort versus 1.3 in controls (p =
0.007), similar to the average of mutations
in only the cases without a yet-definitive
HPMV (Figure S5). These data suggest
that themutation burden inCMTgenes re-
mains the same between patients with a
known versus unknown HPMV and is
significantly greater than the background
load in unaffected controls.
As a further test of this mutational
burdenobservation,wecalculated repeat-edly the average number of rare, nonsynonymous variants in the
58 neuropathy genes in 40 randomly selected individuals from
the BHCMG_EU sample set compared to the 5748 ARIC_EA con-
trols. Upon conclusion of 100 resamplings (with replacement), we
only found three instances inwhich the p valuewas lower than the
p value observed in our original US CMT (subtracting the HPMV)
versus ARIC_EA analysis. These data reinforce the notion that
the background mutation load in these 58 neuropathy genes is
specific to the population of neuropathy patients.
To further investigate our observation of neuropathy gene
mutation burden in neuropathy patients, we analyzed WES
data from an independent cohort of 32 patients (30 families)
from Turkey with a clinical diagnosis of CMT. When compared
to population-matched unrelated Turkish controls, the Turkish
neuropathy cohort had a mutation burden of 2.1 versus 1.6
(p = 0.013) nonsynonymous rare variants per individual, lending
further credence to the mutation burden hypothesis (Figure 4B;
Figure S5). The smaller difference in the number of rare variants
per individual may also reflect a greater number of private vari-
ants in the Turkish population (particularly recessive alleles) or
the contribution of consanguinity in this population.
Functional Testing of the Mutation Burden Hypothesis
We hypothesized that the ‘‘mutation burden’’ observed in the
CMT cohorts would be reflected in the functional consequences
of CMT gene knockdown, and combinations thereof, in a zebra-
fish model. This functional assay evaluated the integrity and
innervation of motor neuron axons along the body axis (Figure 5).
A subset of genes was tested for potential genetic interactionsAugust 18, 2015 ª2015 The Authors 1175
Figure 4. Rare Variant Distribution in Studied Individuals Suggests High Carrier Frequency for Rare Alleles in Neuropathy Genes in Exome
Sequenced Neuropathy Cohort
(A) Distribution of rare variants in neuropathy associated genes in 40 patients of neuropathy cohort (white bars) shows a tendency toward harboring more rare
variants per individual exome as compared to a different extended cohort of 5,748 Europeans from the ARIC-EA study (black bars) observed to have a tendency
toward zero or one rare variants in neuropathy genes.
(B) A similar trend is observed in an ethnically different cohort of patients with neuropathy from Turkey (white bars) as compared to ethnically matched Turkish
control individuals without neuropathy (black bars).and mutation burden effects on phenotype based on our initial
cohort’s observed mutation events. Specifically, we suppressed
each of mfn2, gdap1, abhd12, med25, hspb1, and wnk1 sepa-
rately and in pairwise combinations of sub-effective doses and
tested the functional consequences of the genetic interactions
between the selected CMT genes. Consistent with our hypothe-
sis, we observed increased severity in the phenotype of aberrant
axon extension, branching, pathfinding, and morphology of pe-
ripheral neurons in our zebrafish model when we injected pair-
wise combinations of these genes (Figure 5). In each case, we
observed likely multiplicative effects, although the magnitude
of interaction was unique for each pairing. For example, sub-
effective co-injection of MOs against mfn2 and gdap1, which
by themselves gave no phenotype at the dose tested, yielded
a milder exacerbated phenotype (class I/II motor neuron pathol-
ogy in 80%–100% of embryos tested), whereas co-suppression
of mfn2 and med25 yielded 80%–100% affected embryos, with
one-third of the embryos affected severely (class III/IV). These
data support the prediction of genetic interaction for loss-of-
function events in bona fide CMT genes. To assess the speci-
ficity of our in vivo model, we also tested for genetic interaction
between GDAP1, a bona fide CMT driver, and three genes that
have not been associated previously with peripheral neuropathy.
Two of those are expressed in the CNS and cause other neuro-
pathologies (SIX6: optic nerve atrophy [Carnes et al., 2014];
RP1L1: retinal degeneration and cerebellar disorganization
[Davidson et al., 2013]), and the third is expressed ubiquitously1176 Cell Reports 12, 1169–1183, August 18, 2015 ª2015 The Autho(ANKRD6). We injected sub-effective doses of each of the tested
genes alone and also in pairwise combinations (Figure S6).
Though RP1L1 yields a 20% increase in the percentage of em-
bryos with abnormally formed peripheral neuronal axons when
injected alone, we observed no exacerbation of the phenotype
when each of those genes was suppressed in combination
with GDAP1.
DISCUSSION
Whole-exome sequencing (WES) allows genome-wide assess-
ment of SNV coding variation in the fraction of the human diploid
genome that we can potentially interpret. However, even in ge-
netic conditions with known associated genes, interpretation
can be complicated by the presence of novel variants in more
than one causative gene (Yang et al., 2013, 2014). Additionally,
the contribution of variants in a multiplicity of genes for a single
condition within an individual personal genome and how varia-
tion in these can contribute to or modify the phenotype has rarely
been assessed.
We identified the apparent HPMV and likely primary disease
driver of the neuropathy phenotype in 17/37 (45.9%) families
studied and suggest a potential candidate gene for three
additional families. We discovered a mutational burden of 2.3
damaging variants in CMT patients versus 1.3 in controls for
the 58 neuropathy-associated genes examined (p < 0.0001).
After a highly stringent additional filter consisting of subtractionrs
Figure 5. Functional Assessment of Mutation Burden Hypothesis in a Zebrafish Model
First and second column panels show representative images of acetylated-tubulin (a-AcTub) staining of peripheral neurons in 2-day MO knockdown, single or in
pairwise combinations, zebrafish larvae. Third column panel shows qualitative assessment of morphant fish evaluated as defects in peripheral neuron axon
extension, branching or pathfinding according to the scoring system developed. For pairwise combinations, sub-effective concentrations of each of the gene-
specificMOswere injected as shown in the graphs by the number of abnormal larvae in each category. However, when injected together increased severity in the
phenotype was observed for all the pairwise combinations, suggesting in vivo epistatic effects between these pairs of genes as observed in the a-AcTub
fluorescence images and quantified in the graphs. Asterisks highlight some evidently affected axons. The scoring system used for assessing PNS defects in
zebrafish was developed ad hoc and implemented here in order to best reflect the observations resulting from our experiments. Class I category refers to single
axon defects; class II category refers to two or more axons exhibiting defects with the presence of some normal axons; class III category refers to generalized
axonal defects; class IV category refers to complete absence of axonal extension.of the HPMV, neuropathy patients carry a mutation burden con-
sisting of an average of 1.8 rare variants in neuropathy-related
genes, as compared to an average of 1.3 rare variants in a con-Celltrol population (p = 0.007). A mutation burden (p = 0.013) was
replicated in a second, ethnically distinct CMT cohort in compar-
ison to ethnically matched controls. This mutation burden mayReports 12, 1169–1183, August 18, 2015 ª2015 The Authors 1177
well influence the phenotype, contributing to the clinical hetero-
geneity and the spectrum of severity observed in the disease
(Haldane, 1941). We explored this hypothesis in vivo examining
phenotypic consequences of genetic interaction between select
pairs of neuropathy genes. We observed increased severity of
the phenotype in zebrafish consistent with potential additive
and positive genetic interactions between neuropathy genes.
Our cohort has an intrinsic bias since individuals had previous
extensive clinical and molecular screening for disease-causing
variation in the most common CMT genes prior to consideration
for WES. As anticipated, we found a low frequency of known
mutations as these samples were previously screened for such
variants. We found variants in known CMT or neuropathy genes
in 17 cases, including one (MFN2) showing phenotypic expan-
sion in a CMT1 family. By expanding our candidate list to include
additional neuropathy-associated genes, we achieved a 45.9%
(17/37) mutation detection rate. Furthermore, we identified likely
candidate genes PMP2, SPTLC3, and DNAJB5 in an additional
three families potentially providing molecular insights into
20/37 (54.1%)of the families.Wealsoprovide functional evidence
for the pathogenicity of the identified variants in PMP2 and
SPTLC3 (Figure 2) and the effect of dnajb5 suppression onmotor
neurons (Figure S4). However, conclusive proof for these genes
representing bona fide ‘‘neuropathy disease genes’’ will require
the identification of pathogenic variants in additional patients.
Analysis of the WES data from this neuropathy cohort illus-
trates limitations of clinical phenotyping. Detailed phenotypic in-
formation is required for correlating potential disease-causing
variants to the clinical phenotype of patients. As illustrated in
12 of the study subjects, eight from the initial cohort and four
from the Turkish cohort originally referred for a presumptive
clinical diagnosis of CMT, after a molecular diagnosis by WES
and upon retrospective re-evaluation of clinical records, the
broader spectrum of additional clinical features suggested other
disorders associated with neuropathy. Moreover, these further
refined phenotypes were consistent with the molecular findings
from WES in each of the identified genes (Table S3). The pheno-
type driven paradigm for clinical diagnosis is limited by the
(1) presentation of the patient at the given time, (2) individual
examiner, and (3) underlying assumption of a singular unifying
diagnosis; the latter potentially not applicable to either a muta-
tion aggregation model or a mutation burden hypothesis.
In 29/40 (72.5%) patients, we identified additional ‘‘carrier sta-
tus’’ mutations in other CMT or neuropathy-associated genes
besides the apparent HPMV (Tables 1 and S2). These additional
variants might contribute to the variability of expression of the
clinical phenotype (Haldane, 1941). Furthermore, in the cases
where specific HPMVs were not identified, novel loci potentially
wait to be recognized as main disease drivers (Table S4), but
the mutation burden may still contribute to variable expressivity
of the neuropathy phenotype. It is possible that mutation
burden and combinatorial effects of rare variants in genes that
interact genetically in the same biological pathways, such as
those of tRNA biogenesis, endocytic recycling or mitochondrial
dynamics, modify the phenotype due to synergistic (exemplified
byMFN2 andGDAP1 co-occurringmutations in the samepatient)
or counteracting effects (Klassen et al., 2011; Davis and Katsanis,
2012). Alternatively, or additionally, the cumulative mutation1178 Cell Reports 12, 1169–1183, August 18, 2015 ª2015 The Authoburden in genes dispersed across various biological pathways
or ‘‘networks’’ might interplay to destabilize or compensate the
system and thus modulate the penetrance and/or expressivity of
the overall phenotype. Although robust, the capacity of biological
networks to buffer perturbations may be limited if various muta-
tional events are coincident in a personal genome. Studies of the
human disease network (Goh et al., 2007; Hidalgo et al., 2009) at
the genomic scale will likely contribute to our understanding of
both disease and homeostatic states in human biology.
Genome-wide approaches have shown that rare variants are
more common than previously thought (Coventry et al., 2010;
Marth et al., 2011), a robust observation for both SNV- and
CNV-disease-associated alleles (Boone et al., 2013). The overall
phenotype of a given individual may to a greater extent represent
contribution of either de novo or more recent and private muta-
tional events with bigger effects on the whole system function,
the ‘‘driver’’ genes that occurred in the recent ancestors of the in-
dividual or clan (Lupski et al., 2011), rather than more distributed
common variants shared in a population or throughout several
populations. This mutation burden hypothesis and its role in
clan genomics is further illustrated in CMT1A duplication families
wherein a phenotypic outlier in the family is recognized when the
duplication becomes a triplication (Liu et al., 2014) or a CMT1A
duplication is ‘‘homozygosed’’ in a severe neuropathy patient
born to heterozygous affected parents (Lupski et al., 1991).
Interestingly, within peripheral neuropathies, several disorders
once thought to be mostly caused by environmental factors,
have been subsequently shown to have a genetic susceptibility
component. A key example is provided by CNV at the PMP22
locus. The reciprocal to the CMT1A duplication, deletion of
17p11.2, causes hereditary neuropathy with liability to pressure
palsies (HNPP) (Chance et al., 1993). Trait manifestation is usu-
ally associated with an environmental insult, trauma to a specific
nerve and often those that come anatomically close to the
surface (e.g., the ulnar nerve responsible for the ‘funny bone’
phenomena of numbness and tingling upon hitting the elbow).
Locus-specific molecular studies revealed the majority of indi-
viduals that carry the HNPP deletion go undiagnosed (Turner
et al., 2008) due to phenotypic variability or lack of clinical symp-
toms (Kumar et al., 1999). However, association of the deletion
carrier status with susceptibility to developing carpal tunnel syn-
drome (CTS) has been documented (Cruz-Martinez and Arpa,
1998; Potocki et al., 1999; Del Colle et al., 2003). Additionally,
24 of 51 patients diagnosed with multifocal neuropathies, not
considered a genetic disease, were found to carry the HNPP
deletion. Moreover, 37% of mutation positive subjects had no
family history of neuropathy (Tyson et al., 1996). Consequently,
haploinsufficiency of the dosage-sensitive PMP22 gene, either
by HNPP deletion (CNV) or loss-of-function point mutations
(Nicholson et al., 1994; Shy et al., 2006), has been associated
with susceptibility to milder forms of neuropathy. Furthermore,
haploinsufficiency of the CMT SH3TC2 gene can also confer
subclinical neuropathy phenotypes in heterozygous carriers,
including subclinical axonopathy and median nerve mononeur-
opathy associatedwith susceptibility to CTS (Lupski et al., 2010).
From this perspective, our identification of a PMP2 variant,
a gene whose product has been linked to experimental autoim-
mune neuropathy and both Guillain-Barre syndrome (GBS) andrs
chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP), in one family suggests a potential genetic susceptibility
to autoimmune neuropathy. Haploinsufficiency of other CMT
or neuropathy genes can also contribute to susceptibility to
multifactorial neuropathies. Moreover, a recent study to survey
possible underlying genetic contribution to developing chemo-
therapy-induced peripheral neuropathy (CIPN) due to allelic
variability in known CMT genes identified an association of
PRX heterozygous variants in individuals that developed CIPN
versus controls similarly exposed (Beutler et al., 2014). Addition-
ally, three common SNPs in ARHGEF10 were also associated
with different outcomes of protection and susceptibility to
CIPN in the same cohort (Beutler et al., 2014). These findings
support and highlight one of the main hypotheses from the pre-
sent study; themutation burden of carrier status, for neuropathy-
associated rare variant recessive alleles, in clinically unaffected
individuals can poise the organism to develop other types of
complex neuropathies later in life upon gene-environment inter-
actions (GxE). External insults, chemical or mechanical; other
pathologic processes like diabetes or infection; or aging with
concomitant prolonged exposures and/or reduced biological
function of cells (e.g., SSBR, gene transcription, protein pro-
cessing and folding, etc.) or functional units like the neuron can
be the critical factor for the system to express the disease later
in life. This might also be true for other traits thought to be com-
plex and having a major environmental influence with a reduced
genetic component that have been elusive to other approaches.
Rather than single-locus strong associations across popula-
tions, each individual with such a given complex disorder can
carry a handful of rare/private variants in a variety of genes in
their personal genome that are important for the development
of the disease process and that through an oligogenic model
confer susceptibility to the individual to develop the disorder
upon additional factors such as diet, exposures, aging, etc.
In summary, our studies of rare genomic variants in neuropa-
thy identify known pathogenic alleles, novel variants in known
disease genes, and further document phenotypic expansion
for disease gene traits. We identified three potential novel candi-
date neuropathy ‘‘disease genes’’ as supported by both genetic
and functional studies. Moreover, we provide evidence that
genome-wide studies and molecular diagnosis can further
assist interpretation of a clinically based differential diagnosis.
Of note, systematic analyses of genes implicated in neuropathy
reveal a mutation burden in patients compared with unaffected
control populations and zebrafish model organism studies
show gene interactions for genes implicated by mutation burden
in individual families. This mutation burden is consistent with the
concept of clan genomics (Lupski et al., 2011) contributing
significantly to both Mendelian and common/complex disease
trait manifestation.
EXPERIMENTAL PROCEDURES
Samples
We performed WES through the Baylor-Hopkins Center for Mendelian
Genomics (BHCMG). Written informed consent from all participating subjects
was obtained for DNA and genetic analyses though a Baylor College of Med-
icine Institutional Review Board approved protocol and also approved by the
BHCMG ELSI committee for inclusion into the BHCMG sequencing project.CellSome of these samples had been collected and stored over decades; thus,
DNA of parents or other family members was not always available for addi-
tional testing and co-segregation analyses.
Exome Sequencing
We performed whole-exome next-generation sequencing according to previ-
ously published methods (Lupski et al., 2013; see Supplemental Experimental
Procedures for details), producing an average of 9.25 Gb of raw data per
exome and achieving 93.53 average depth of coverage (median coverage =
973) per sample with >90% of the captured bases covered at 203 (Table S5).
Variant data generated will be released and deposited into the NCBI database
of Genotypes and Phenotypes (dbGaP: http://www.ncbi.nlm.nih.gov/gap) as
part of the Centers for Mendelian Genomics research initiative.
Variant Annotation Pipeline
Variant calling from the aligned BAM files was performed using the ATLAS
(Shen et al., 2010) and SAMtools suites (Li et al., 2009). Annotation was per-
formed using Sacbe, an in-house developed annotation pipeline (Gonzaga-
Jauregui et al., 2013) based on ANNOVAR (Wang et al., 2010) and custom
scripts (see Supplemental Experimental Procedures for details).
Data Analysis
Weperformed an initial analysis focusing on a list of 74 CMT and other neurop-
athy-associated genes (Table S6). Additionally, we interrogated a list of candi-
date CMT genes (Table S7) based on first degree interactors of known CMT
genes and performed a second pass analysis in those cases where we did
not identify candidate mutations in CMT genes.
The number of rare (i.e., minor allele frequency of%1% in TGP, NHLBI ESP,
and the European subset of NHLBI ESP) nonsynonymous variants in 58 well-
established CMT genes (Table S8) was computed for each sample of the
neuropathy cohort and for 5,748 Europeans from the ARIC (Atherosclerosis
Risk in Communities study) cohort, a large population-based study of cardio-
vascular disease and its risk factors. The average number of rare nonsynony-
mous variants was then compared between the neuropathy and ARIC study
samples using a non-parametric Mann-Whitney-Wilcoxon test. A permutation
procedure with 100,000 iterations was performed to determine statistical sig-
nificance. For the second CMT cohort of Turkish descent, a set of 472 Turkish
controls was used that was sequenced and analyzed using identical protocols,
platforms, and standards to those of the cases.
Functional Experiments
See Supplemental Experimental Procedures for details.
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The accession numbers for the exomes reported in this manuscript consented
for data deposition into dbGaP are SAMN03361200, SAMN03361023,
SAMN03361097, SAMN03361077, SAMN03361019, SAMN03360995,
SAMN03361140, SAMN03361181, SAMN03361070, SAMN03361130,
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